Analysts’ Viewpoint
Rise in prevalence of cancer, advancements in cancer biotechnology, increase in demand for targeted therapies, and favorable reimbursement policies are the major factors driving the global cancer biologics market. Cancer continues to be a significant health challenge globally, with 10 million fatalities in 2020. Surge in need for effective and innovative treatments of cancer is propelling the cancer biologics market growth. Furthermore, advancements in understanding cancer biology, identifying specific molecular targets, and developing biologic drugs that can selectively target and inhibit cancer cells are expected to accelerate market expansion.
Rise in demand for targeted therapies, as these offer improved treatment outcomes and reduced side effects compared to traditional chemotherapy, offers lucrative opportunities to market players. Moreover, favorable reimbursement policies by governments and insurance providers have encouraged the adoption of cancer biologics, ensuring wider patient access to these advanced treatments.
The cancer biologics market encompasses a range of therapeutic products developed through biotechnology to treat various types of cancer. Biologic drugs are derived from living organisms, such as cells or proteins, and are designed to target specific cancer cells or pathways.
These drugs include monoclonal antibodies, vaccines, and cell-based therapies. These work by enhancing immune response, blocking tumor growth signals, or directly attacking cancer cells.
The market has witnessed significant developments in the past few years, including approval of novel biologic therapies, expansion of targeted therapies, and advancements in immunotherapies.
Targeted therapies, such as HER2-targeted antibodies for breast cancer or EGFR inhibitors for lung cancer, have shown improved treatment outcomes. Immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies have demonstrated remarkable success in certain cancers.
The market continues to evolve with ongoing research and development efforts to discover new therapeutic targets and optimize treatment approaches, aiming to provide more effective and personalized options for cancer patients.
Rise in number of cancer cases across the globe has increased the need for effective and targeted therapies to combat this complex disease.
Surge in cancer incidence can be attributed to several factors. Population growth, aging population, and lifestyle changes have contributed to the increasing burden of cancer. Additionally, improved diagnostic techniques and increased awareness have led to better detection and reporting of cancer cases.
Rise in cancer cases has spurred significant advancements in the field of cancer treatment, with a particular focus on biologic drugs. Biologics, derived from living organisms or produced using biotechnology, offer unique advantages over traditional chemotherapy drugs.
Biologics can target specific molecules or pathways involved in cancer growth and progression, leading to more precise and personalized treatment approaches. Increase in cancer incidence has prompted greater research and development efforts in the field of oncology biologics.
Pharmaceutical companies, academic institutions, and research organizations are investing significantly in developing novel biologic drugs and conducting clinical trials to evaluate their safety and efficacy. The focus is not only on improving existing treatments, but also on discovering innovative approaches to combatting cancer.
Advancements in biotechnology are playing a crucial role in driving the global cancer biologics market demand. Biotechnology has revolutionized the field of cancer research and treatment by enabling the development of innovative biologic drugs with enhanced specificity, efficacy, and safety profiles.
One of the key advancements in biotechnology is the ability to produce monoclonal antibodies (mAbs). These biologic drugs are engineered to target specific molecules or proteins expressed on the surface of cancer cells.
By binding to these targets, mAbs can block signaling pathways, inhibit tumor growth, and stimulate immune responses against cancer cells. Development of techniques such as hybridoma technology and recombinant DNA technology has facilitated large-scale production of mAbs with high precision and consistency.
Advent of recombinant DNA technology and genetic engineering has enabled the creation of novel biologic drugs for cancer treatment. This technology enables the manipulation and modification of genes to produce therapeutic proteins with desired characteristics. For instance, the production of erythropoietin (EPO) using recombinant DNA technology has revolutionized the treatment of anemia associated with cancer and chemotherapy.
Development of targeted therapies is another breakthrough in biotechnology that is driving global cancer biologics market value. These therapies focus on specific molecular targets that play a critical role in cancer growth and progression. These are designed to inhibit the activity of these targets and disrupt the signaling pathways involved in tumor development.
Targeted therapies can be small molecules or biologic drugs, such as tyrosine kinase inhibitors or proteasome inhibitors, which selectively target cancer cells while sparing healthy cells.
Biotechnology has facilitated significant advancements in cancer immunotherapies. Immune checkpoint inhibitors, a form of immunotherapy, block inhibitory signals that cancer cells use to evade the immune system's attack.
This approach has shown remarkable success in treating various types of cancer, including melanoma, lung cancer, and bladder cancer. Biotechnology has enabled the production of these biologic drugs that can restore and enhance the body's immune response against cancer cells.
In terms of drug class, the monoclonal antibodies (mAbs) segment accounted for the largest global cancer biologics market share in 2022. This is ascribed to their unique properties and therapeutic potential.
One of the key reasons for their prominence is the ability to specifically target cancer cells or tumor-associated antigens, while sparing healthy cells. This targeted approach minimizes off-target effects and reduces the risk of systemic toxicity, making mAbs an attractive treatment option.
Monoclonal antibodies continue to be actively researched and developed for novel targets and therapeutic approaches. Emergence of bispecific antibodies, capable of simultaneously binding to two different targets, has gained attention in the past few years. These antibodies can be engineered to engage both cancer cells and immune cells, facilitating the destruction of cancer cells through immune-mediated mechanisms. Bispecific antibodies, such as blinatumomab (Blincyto) for acute lymphoblastic leukemia, represent a promising advancement in cancer treatment.
Advancements in antibody engineering and optimization techniques have enabled the development of next-generation monoclonal antibodies with improved efficacy and reduced immunogenicity. Antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP) properties have shown increased tumor-killing capabilities.
Based on application, the blood cancer segment dominated the global cancer biologics industry in 2022. The segment includes leukemia, lymphoma, and multiple myeloma. Blood cancers are a diverse group of malignancies with distinct molecular and genetic characteristics, making them amenable to targeted therapies.
This has led to the development of numerous biologic drugs that specifically target the underlying mechanisms driving blood cancer growth and proliferation. Prevalence of blood cancer is high globally, and a wide range of biologics are available for treatment.
Ongoing research & development efforts in the field of blood cancer biologics continue to expand treatment options. Clinical trials are exploring novel monoclonal antibodies, antibody-drug conjugates, CAR-T cell therapies, and other biologic approaches to further enhance the effectiveness of treatment.
In terms of end-user, the hospitals segment accounted for the largest market share in 2022. Hospitals have a multidisciplinary approach to cancer care. These settings have a team of healthcare professionals, including medical oncologists, hematologists, radiation oncologists, and specialized nurses, who collaborate to develop comprehensive treatment plans for cancer patients.
This multidisciplinary approach facilitates the integration of cancer biologics into the overall treatment strategy, ensuring proper patient selection, monitoring, and management.
Hospitals often have established partnerships and collaborations with pharmaceutical companies and research institutions. These collaborations enable hospitals to participate in clinical trials and access the latest advancements in cancer biologics. Therefore, they have the advantage of early adoption and integration of new biologic therapies into their treatment protocols.
The ability to provide comprehensive care is another factor driving the hospitals segment. Cancer treatment often involves a combination of therapies, including surgery, radiation therapy, chemotherapy, and biologic therapies. Hospitals can offer all these treatment modalities under one roof, ensuring seamless coordination and continuity of care for patients.
As per cancer biologics market trends, North America emerged as a major market for cancer biologics in 2022. This is ascribed to advanced healthcare infrastructure, strong research & development capabilities, favorable regulatory environment, and high healthcare expenditure in the region.
North America is also home to prominent pharmaceutical companies and biotechnology firms that are at the forefront of cancer research and innovation. These companies have the expertise and resources to invest in the development of biologic drugs and conduct clinical trials to evaluate their safety and efficacy.
The region's strong research & development capabilities contribute to the continuous pipeline of new and improved cancer biologics.
Asia Pacific has witnessed steady rise in cancer cases, attributed to factors such as population growth, aging population, and lifestyle changes. This surge in cancer incidence has increased demand for effective cancer treatments, including biologic drugs.
Improving healthcare infrastructure is another crucial factor driving the cancer biologics market size in Asia Pacific. Countries in the region have been investing significantly in healthcare infrastructure, including the establishment of advanced hospitals, cancer centers, and research institutes. This improved infrastructure enables the development, production, and distribution of biologic drugs for cancer treatment, enhancing patient access to these therapies.
The global cancer biologics market is fragmented, with the presence of large number of players. Companies in the market have adopted strategies such as investment in R&D, product portfolio expansion, and merger & acquisition in order to increase market share and presence.
F. Hoffmann-La Roche Ltd., Amgen, Inc., Pfizer, Inc., GSK plc., Bristol-Myers Squibb Company, Abbott, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., and Johnson & Johnson Services, Inc.
The cancer biologics market report profiles top players based on various factors including a company overview, financial summary, strategies, product portfolio, segments, and recent advancements.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 94.5 Bn |
|
Forecast Value in 2031 |
More than US$ 185.0 Bn |
|
CAGR - 2023-2031 |
7.7 % |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 94.5 Bn in 2022
It is projected to reach US$ 185.0 Bn by 2031
The industry is anticipated to expand at a 7.7% from 2023 to 2031
The monoclonal antibody (mAb) segment held the leading share in 2022
North America is expected to account for largest share from 2022 to 2031
F. Hoffmann-La Roche Ltd., Amgen, Inc., Pfizer, Inc., GSK plc, Bristol-Myers Squibb Company, Abbott, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., and Johnson & Johnson Services, Inc. are the prominent players in the market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Biologics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Biologics Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Overview: Advances in Cancer Diagnostics & Therapeutics
5.3. Cancer Incidence & Prevalence Rate by Region/Key Countries
5.4. Key Product Brand Analysis
5.5. Covid-19 Impact Analysis
6. Global Cancer Biologics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Monoclonal Antibodies (mAb)
6.3.1.1. Naked mAb
6.3.1.2. Conjugated mAb
6.3.1.3. Bispecific mAb
6.3.2. Recombinants Proteins
6.3.3. Cancer Growth Inhibitors
6.3.3.1. Tyrosine Kinase Inhibitors
6.3.3.2. mTOR Inhibitors
6.3.3.3. Others (Proteasome Inhibitors)
6.3.4. Vaccines
6.3.4.1. Preventive Vaccines
6.3.4.2. Therapeutic Vaccines
6.3.5. CAR-T Cells
6.3.6. Angiogenesis Inhibitors
6.3.7. Interleukins (IL)
6.3.8. Others (Interferons (IFN), Gene Therapy, etc.)
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Cancer Biologics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Blood Cancer
7.3.2. Lung Cancer
7.3.3. Breast Cancer
7.3.4. Colorectal Cancer
7.3.5. Prostate Cancer
7.3.6. Gastric Cancer
7.3.7. Ovarian Cancer
7.3.8. Others (Skin, Liver cancer, etc.)
7.4. Market Attractiveness Analysis, by Application
8. Global Cancer Biologics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals
8.3.2. Cancer Centers
8.3.3. Academics & Research Institutes
8.4. Market Attractiveness Analysis, by End-user
9. Global Cancer Biologics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cancer Biologics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017-2031
10.2.1. Monoclonal Antibodies (mAb)
10.2.1.1. Naked mAb
10.2.1.2. Conjugated mAb
10.2.1.3. Bispecific mAb
10.2.2. Recombinants Proteins
10.2.3. Cancer Growth Inhibitors
10.2.3.1. Tyrosine Kinase Inhibitors
10.2.3.2. mTOR Inhibitors
10.2.3.3. Others (Proteasome Inhibitors)
10.2.4. Vaccines
10.2.4.1. Preventive Vaccines
10.2.4.2. Therapeutic Vaccines
10.2.5. CAR-T Cells
10.2.6. Angiogenesis Inhibitors
10.2.7. Interleukins (IL)
10.2.8. Others (Interferons (IFN), Gene Therapy, etc.)
10.3. Market Value Forecast, by Application, 2017-2031
10.3.1. Blood Cancer
10.3.2. Lung Cancer
10.3.3. Breast Cancer
10.3.4. Colorectal Cancer
10.3.5. Prostate Cancer
10.3.6. Gastric Cancer
10.3.7. Ovarian Cancer
10.3.8. Others (Skin, Liver cancer, etc.)
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals
10.4.2. Cancer Centers
10.4.3. Academics& Research Institutes
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Cancer Biologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. Monoclonal Antibodies (mAb)
11.2.1.1. Naked mAb
11.2.1.2. Conjugated mAb
11.2.1.3. Bispecific mAb
11.2.2. Recombinants Proteins
11.2.3. Cancer Growth Inhibitors
11.2.3.1. Tyrosine Kinase Inhibitors
11.2.3.2. mTOR Inhibitors
11.2.3.3. Others (Proteasome Inhibitors)
11.2.4. Vaccines
11.2.4.1. Preventive Vaccines
11.2.4.2. Therapeutic Vaccines
11.2.5. CAR-T Cells
11.2.6. Angiogenesis Inhibitors
11.2.7. Interleukins (IL)
11.2.8. Others (Interferons (IFN), Gene Therapy, etc.)
11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Blood Cancer
11.3.2. Lung Cancer
11.3.3. Breast Cancer
11.3.4. Colorectal Cancer
11.3.5. Prostate Cancer
11.3.6. Gastric Cancer
11.3.7. Ovarian Cancer
11.3.8. Others (Skin, Liver cancer, etc.)
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals
11.4.2. Cancer Centers
11.4.3. Academics& Research Institutes
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Cancer Biologics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. Monoclonal Antibodies (mAb)
12.2.1.1. Naked mAb
12.2.1.2. Conjugated mAb
12.2.1.3. Bispecific mAb
12.2.2. Recombinants Proteins
12.2.3. Cancer Growth Inhibitors
12.2.3.1. Tyrosine Kinase Inhibitors
12.2.3.2. mTOR Inhibitors
12.2.3.3. Others (Proteasome Inhibitors)
12.2.4. Vaccines
12.2.4.1. Preventive Vaccines
12.2.4.2. Therapeutic Vaccines
12.2.5. CAR-T Cells
12.2.6. Angiogenesis Inhibitors
12.2.7. Interleukins (IL)
12.2.8. Others (Interferons (IFN), Gene Therapy, etc.)
12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Blood Cancer
12.3.2. Lung Cancer
12.3.3. Breast Cancer
12.3.4. Colorectal Cancer
12.3.5. Prostate Cancer
12.3.6. Gastric Cancer
12.3.7. Ovarian Cancer
12.3.8. Others (Skin, Liver cancer, etc.)
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals
12.4.2. Cancer Centers
12.4.3. Academics& Research Institutes
12.5. Market Value Forecast, by Country, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Cancer Biologics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. Monoclonal Antibodies (mAb)
13.2.1.1. Naked mAb
13.2.1.2. Conjugated mAb
13.2.1.3. Bispecific mAb
13.2.2. Recombinants Proteins
13.2.3. Cancer Growth Inhibitors
13.2.3.1. Tyrosine Kinase Inhibitors
13.2.3.2. mTOR Inhibitors
13.2.3.3. Others (Proteasome Inhibitors)
13.2.4. Vaccines
13.2.4.1. Preventive Vaccines
13.2.4.2. Therapeutic Vaccines
13.2.5. CAR-T Cells
13.2.6. Angiogenesis Inhibitors
13.2.7. Interleukins (IL)
13.2.8. Others (Interferons (IFN), Gene Therapy, etc.)
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Blood Cancer
13.3.2. Lung Cancer
13.3.3. Breast Cancer
13.3.4. Colorectal Cancer
13.3.5. Prostate Cancer
13.3.6. Gastric Cancer
13.3.7. Ovarian Cancer
13.3.8. Others (Skin, Liver cancer, etc.)
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals
13.4.2. Cancer Centers
13.4.3. Academics& Research Institutes
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Cancer Biologics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. Monoclonal Antibodies (mAb)
14.2.1.1. Naked mAb
14.2.1.2. Conjugated mAb
14.2.1.3. Bispecific mAb
14.2.2. Recombinants Proteins
14.2.3. Cancer Growth Inhibitors
14.2.3.1. Tyrosine Kinase Inhibitors
14.2.3.2. mTOR Inhibitors
14.2.3.3. Others (Proteasome Inhibitors)
14.2.4. Vaccines
14.2.4.1. Preventive Vaccines
14.2.4.2. Therapeutic Vaccines
14.2.5. CAR-T Cells
14.2.6. Angiogenesis Inhibitors
14.2.7. Interleukins (IL)
14.2.8. Others (Interferons (IFN), Gene Therapy, etc.)
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Blood Cancer
14.3.2. Lung Cancer
14.3.3. Breast Cancer
14.3.4. Colorectal Cancer
14.3.5. Prostate Cancer
14.3.6. Gastric Cancer
14.3.7. Ovarian Cancer
14.3.8. Others (Skin, Liver cancer, etc.)
14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Hospitals
14.4.2. Cancer Centers
14.4.3. Academics& Research Institutes
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Amgen, Inc.
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Pfizer, Inc.
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. GSK plc
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Bristol-Myers Squibb Company
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Abbott
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. AstraZeneca
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Eli Lilly and Company
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Gilead Sciences, Inc.
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Johnson & Johnson Services, Inc.
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments
List of Tables
Table 01: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 02: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031
Table 03: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031
Table 04: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031
Table 05: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 06: Global Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 07: Global Cancer Biologics Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 08: North America Cancer Biologics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 09: North America Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 10: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031
Table 11: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031
Table 12: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031
Table 13: North America Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 14: North America Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 15: Europe Cancer Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 16: Europe Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 17: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031
Table 18: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031
Table 19: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031
Table 20: Europe Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 21: Europe Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 22: Asia Pacific Cancer Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 23: Asia Pacific Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 24: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031
Table 25: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031
Table 26: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031
Table 27: Asia Pacific Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 28: Asia Pacific Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 29: Latin America Cancer Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 30: Latin America Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 31: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031
Table 32: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031
Table 33: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031
Table 34: Latin America Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 35: Latin America Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 36: Middle East and Africa Cancer Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 37: Middle East and Africa Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 38: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031
Table 39: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031
Table 40: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031
Table 41: Middle East and Africa Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 42: Middle East and Africa Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Cancer Biologics Market Value Share, by Drug Class, 2022
Figure 03: Global Cancer Biologics Market Value Share, by Application, 2022
Figure 04: Global Cancer Biologics Market Value Share, by End-user, 2022
Figure 05: Global Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 06: Global Cancer Biologics Market Revenue (US$ Mn), by Monoclonal Antibodies (mAb), 2017-2031
Figure 07: Global Cancer Biologics Market Revenue (US$ Mn), by Recombinants Proteins, 2017-2031
Figure 08: Global Cancer Biologics Market Revenue (US$ Mn), by Cancer Growth Inhibitors, 2017-2031
Figure 09: Global Cancer Biologics Market Revenue (US$ Mn), by Vaccines, 2017-2031
Figure 10: Global Cancer Biologics Market Revenue (US$ Mn), by CAR-T Cells, 2017-2031
Figure 11: Global Cancer Biologics Market Revenue (US$ Mn), by Angiogenesis Inhibitors, 2017-2031
Figure 12: Global Cancer Biologics Market Revenue (US$ Mn), by Interleukins (IL), 2017-2031
Figure 13: Global Cancer Biologics Market Revenue (US$ Mn), by Others, 2017-2031
Figure 14: Global Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 15: Global Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 16: Global Cancer Biologics Market Revenue (US$ Mn), by Blood Cancer, 2017-2031
Figure 17: Global Cancer Biologics Market Revenue (US$ Mn), by Lung Cancer, 2017-2031
Figure 18: Global Cancer Biologics Market Revenue (US$ Mn), by Breast Cancer, 2017-2031
Figure 19: Global Cancer Biologics Market Revenue (US$ Mn), by Colorectal Cancer, 2017-2031
Figure 20: Global Cancer Biologics Market Revenue (US$ Mn), by Prostate Cancer, 2017-2031
Figure 21: Global Cancer Biologics Market Revenue (US$ Mn), by Gastric Cancer, 2017-2031
Figure 22: Global Cancer Biologics Market Revenue (US$ Mn), by Ovarian Cancer, 2017-2031
Figure 23: Global Cancer Biologics Market Revenue (US$ Mn), by Other Cancer, 2017-2031
Figure 24: Global Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 25: Global Cancer Biologics Market Value Share Analysis, by Region, 2022 and 2031
Figure 26: Global Cancer Biologics Market Attractiveness Analysis, by Region, 2023-2031
Figure 27: North America Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 28: North America Cancer Biologics Market Value Share Analysis, by Country, 2022 and 2031
Figure 29: North America Cancer Biologics Market Attractiveness Analysis, by Country, 2023-2031
Figure 30: North America Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 31: North America Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 32: North America Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 33: North America Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 34: North America Cancer Biologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 35: North America Cancer Biologics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 36: Europe Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 37: Europe Cancer Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 38: Europe Cancer Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 39: Europe Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 40: Europe Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 41: Europe Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 42: Europe Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 43: Europe Cancer Biologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 44: Europe Cancer Biologics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 45: Asia Pacific Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 46: Asia Pacific Cancer Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 47: Asia Pacific Cancer Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 48: Asia Pacific Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 49: Asia Pacific Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 50: Asia Pacific Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 51: Asia Pacific Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 52: Asia Pacific Cancer Biologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 53: Asia Pacific Cancer Biologics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 54: Latin America Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 55: Latin America Cancer Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 56: Latin America Cancer Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 57: Latin America Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 58: Latin America Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 59: Latin America Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 60: Latin America Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 61: Latin America Cancer Biologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 62: Latin America Cancer Biologics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 63: Middle East and Africa Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 64: Middle East and Africa Cancer Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 65: Middle East and Africa Cancer Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 66: Middle East and Africa Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 67: Middle East and Africa Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 68: Middle East and Africa Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031
Figure 69: Middle East and Africa Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031
Figure 70: Middle East and Africa Cancer Biologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 71: Middle East and Africa Cancer Biologics Market Attractiveness Analysis, by End-user, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cancer Biologics Market
*86 figures and 60 tables includes